News
PTPI
--
0.00%
--
Petros Pharmaceuticals GAAP EPS of -$0.01, revenue of $2.47M
Petros Pharmaceuticals press release (NASDAQ:PTPI): Q1 GAAP EPS of -$0.01. Revenue of $2.47M (-39.5% Y/Y).
Seekingalpha · 5d ago
BRIEF-Petros Pharmaceuticals Reports Q1 2022 Results
reuters.com · 5d ago
-- Earnings Flash (PTPI) PETROS PHARMACEUTICALS Reports Q1 Revenue $2.5M
MT Newswires · 5d ago
Petros Pharmaceuticals To Pursue 505(B)(2) Pathway For H-100, Company's Novel Topical Investigational Treatment For Peyronie's Disease Which Impacts More Than 1 In 10 Men In The Us
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today they will be pursuing the 505(b)(2) pathway for its investigational agent, H-100™, a novel,
Benzinga · 05/03 13:24
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US
Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local Medication Permeation Against Peyronie’s Disease, Which is Currently Predominantly Treated Surgically, ...
GlobeNewswire · 05/03 13:23
28 Stocks Moving in Thursday's Pre-Market Session
Gainers T Stamp Inc. (NASDAQ: IDAI) shares rose 103.3% to $4.27 in pre-market trading after gaining over 8% on Wednesday. Trust Stamp recently posted Q4 net sales of $2.1 million.
Benzinga · 04/28 10:30
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV
LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's Hotel & Casino in Las Vegas, NV.comThe Planet Micr...
ACCESSWIRE · 04/27 13:00
Petros Pharmaceuticals Engages Massachusetts General Hospital In Sponsored Research Agreement For Tissue-Specific Oxygenation Sensor Technology; Terms Not Disclosed
Petros Pharmaceuticals, Inc. ((Petros, NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces it has entered into a Sponsored Research Agreement (SRA) and an Option Agreement with the
Benzinga · 04/26 13:17
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology
Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device TherapyNEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Petros, Nasdaq: PTPI), a leading provider of therapeuti...
GlobeNewswire · 04/26 13:15
AXSM, SEV and HUSA among mid-day movers
Gainers: Checkmate Pharmaceuticals (CMPI) +332%. Sono Group (SEV) +66%. ToughBuilt Industries (TBLT) +55%. Petros Pharmaceuticals (PTPI) +40%. Axsome Therapeutics (AXSM) +25%. Cyren (CYRN) +22%. Super Micro Computer (SMCI) +21%. Pulse
Seekingalpha · 04/19 16:28
Petros soars on label comprehension study's positive results for erectile dysfunction drug
Shares of micro-cap Petros Pharmaceuticals (NASDAQ:PTPI) have jumped 33.7% on Tuesday morning, after the company announced what it deemed to be positive results from its over-the-counter draft label comprehension study
Seekingalpha · 04/19 14:12
Checkmate, Petros Pharmaceuticals top healthcare gainers; Lyra, Diffusion lead losers' pack
Gainers: Checkmate Pharmaceuticals (CMPI) +333%. Petros Pharmaceuticals (PTPI) +55%. Axsome Therapeutics (AXSM) +23%. Avinger (AVGR) +11%. Processa Pharmaceuticals (PCSA) +10%. Losers: Lyra Therapeutics (LYRA) -16%. Diffusion Pharmaceuticals (DFFN) -15%. C...
Seekingalpha · 04/19 14:04
Top Midday Gainers
MT Newswires · 04/19 13:40
BRIEF-Petros Announces Results Of OTC Label Comprehension Study For Erectile Dysfunction Drug Stendra
reuters.com · 04/19 13:21
Petros Pharmaceuticals Announces Results Of STENDRA OTC Label Comprehension Study; Says 'These results suggest that the draft drug facts labeling language as written may be appropriate for submission to the FDA for review for over-the-counter labeling'
Clear Understanding of STENDRA OTC Label to be Key Element in OTC Development Program Company is Pursuing NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the
Benzinga · 04/19 13:20
Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)
Clear Understanding of STENDRA OTC Label to be Key Element in OTC Development Program Company is PursuingNEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutic...
GlobeNewswire · 04/19 13:15
Petros Pharmaceutical Says Comprehension Study Supports Over-the-Counter Labeling for Stendra; Shares Rise
MT Newswires · 04/19 10:41
Petros Pharmaceuticals GAAP EPS of -$0.83, revenue of $7.81M
Petros Pharmaceuticals press release (NASDAQ:PTPI): FY GAAP EPS of -$0.83. Revenue of $7.81M (-18.3% Y/Y).
Seekingalpha · 04/01 11:33
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the ...
GlobeNewswire · 03/03 13:00
Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health
Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a collaboration agreement with celebrity physician Dr. Drew Pinsky ("Dr. Drew") to raise awareness, foster dialogue, educat...
PR Newswire · 02/01 14:15
Webull provides a variety of real-time PTPI stock news. You can receive the latest news about Petros Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About PTPI
Petros Pharmaceuticals, Inc. is a pharmaceutical company that is focused on men’s health therapeutics with a range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing and distribution. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.